Early Strides for Takeda’s Qdenga In Brazil, India Deal Adds New Dimension

Takeda’s head of multi-country organization, India and Southeast Asia, Dion Warren, tells Scrip how things are shaping for Qdenga in Brazil’s public vaccination program and outlines the contours, including pricing aspects, of the deal with Biological E for the dengue vaccine. The US IND application for the jab is still open.

Takeda's Qdenga rolls out in Brazil • Source: Shutterstock

Takeda Pharmaceutical Co. Ltd. appears to have made important early strides with Qdenga in Brazil, where the dengue tetravalent vaccine has been rolled out in a public program, even as the Japanese company sets out to bolster manufacturing capacity for the jab via a strategic alliance in India.

Dion Warren, head of multi-country organization, India and Southeast Asia, Takeda Pharmaceuticals, indicated that Brazil's Ministry of Health had in December 2023 announced plans to integrate the Qdenga vaccine into its public health service, Sistema Único de Saúde (SUS) and more than 3 million people are to be

“The program in Brazil has started recently and is going well,” Warren told

Regeneron Wins PCSK9 Court Battle Against Amgen

16 May 2025

• By Alaric DeArment

A federal court jury found Amgen liable for violating antitrust laws in allegedly preventing Praluent from competing against Repatha.

Lupin CEO On Trump’s Most Favored Nation Policy, Tariffs, Firm’s Five-Year Plan

16 May 2025

• By Vibha Ravi

Lupin CEO Vinita Gupta speaks on Trump’s most favored nation policy, the Inflation Reduction Act’s “pill penalty” and other developments in the US, a major market for the company. The company also outlines a five-year plan focused on complex generics and technology platforms.